Cathie Wood’s Ark Bought More Teradyne (TER)… Should You?
Cathie Wood is doubling down on Teradyne, a robotics and semiconductor test powerhouse with a $1B buyback plan and big AI dreams. Should investors follow? Our fun, fact-filled breakdown has you covered.
Paul Tudor Jones Loves IWM. Should You?
Paul Tudor Jones is going heavy on small caps—and maybe prepping for AI-induced doom. With 1,350+ positions and an options playbook that could fill a library, what’s his real bet? And more importantly: should you follow? Read on, but don’t YOLO.
GAMCO Investors Is Full of Winners — Except Paramount (PARA): Why This One Dud Might Finally Shine
Is Paramount Global a value trap—or a future media giant in disguise? Streaming growth, big-name backers like GAMCO and Vanguard, and Apple buyout rumors make this drama worth watching. 🍿🎥
ACADIA Pharmaceuticals: Biotech Powerhouse Baker Bros Still Believes. Should You Buy In?
Biotech heavyweight Baker Bros still owns over 25% of ACADIA Pharmaceuticals (ACAD), and the stock is heating up. With expanding revenue, a rich CNS pipeline, and smart money backing it, is this the comeback story investors have been waiting for?
Baker Bros. Advisors Just Added to Kymera. Should You Buy the Stock?
Baker Bros. just dropped $28.8M on Kymera Therapeutics. Insane confidence or brilliant foresight? We decode the science, strategy, and stats—including $775M cash, STAT6 breakthroughs, and the risk baked into that juicy pipeline. Should you take a nibble?
Lionsgate Studios: Insiders Are Buying. Should the Stock Get the Lion's Share of Your Portfolio?
🦁 Liberty 77 Capital, led by ex-Treasury Secretary Steven Mnuchin, bought over 8 million shares of Lionsgate Studios (NYSE: LION). Revenues are up, insiders are bullish, and the studio is freshly split from Starz. Is it showtime—or a risky sequel?
John Paulson Is Loading Up on Perpetua Resources. Should You?
John Paulson knows a good discount when he sees one—and he just grabbed another $100M worth of Perpetua Resources (PPTA). But what is this gold-and-antimony play really about? From Idaho mines to strategic minerals and a wink at squirrel invasions, we break it all down.
John Paulson Is Loading Up on Bausch Health. Should You?
John Paulson just doubled down on Bausch Health 💊 — but should you? A look at insider moves, deep discounts, and a possible comeback no one saw coming.
Apple Remains Warren Buffett’s Top Stock — Should You Still Bite?
Buffett’s got $60 billion riding on Apple. Services are booming. iPhone addiction remains. But is it still worth your bite — or should you wait for a sweeter dip? 🍏🤔
Daniel Loeb Still Thinks PG&E Stands for Purchase, Grab & Enjoy
PG&E has gone from fiery headlines to financial footing—and Daniel Loeb’s Third Point is all-in. With 14% of his portfolio riding on PCG, a growing customer base, and wildfire risks contained (for now), is this survivor stock worth a second look?
2 comments
|